Navigation Links
ADVENTRX Submits Exelbine™ New Drug Application
Date:11/3/2010

e potential for the FDA to impose other requirements to be completed before or after approval of the Exelbine NDA, including that the FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical studies; ADVENTRX's reliance on third parties to assist with its bioequivalence trials, regulatory submissions, manufacturing and other important aspects of the Exelbine development program, and the risk that FDA approval may be delayed if their performance is found to have been substandard; the possibility that a patent issued based on ADVENTRX's U.S. patent application entitled "Compositions for Delivering Highly Water Soluble Drugs" will not provide sufficient protection and market exclusivity for Exelbine; the risk that any patent issued to ADVENTRX may be challenged, invalidated, infringed or circumvented by third parties, including by ADVENTRX's competitors; the risk that ADVENTRX does not receive FDA approval of Exelbine on a timely basis, or at all; ADVENTRX's dependence on the success of Exelbine as its first product candidate to be submitted for regulatory approval; the potential that ADVENTRX may require substantial additional funding in order to obtain FDA approval for and commercialize Exelbine, and the risk that ADVENTRX may not be able to raise sufficient capital when needed, or at all; the potential for ADVENTRX to enter into a commercial partnership or other strategic transaction relating to Exelbine and that such partnership or transaction may not succeed in commercializing Exelbine; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... 2012  Stockell Healthcare Systems is pleased to announce ... healthcare provider headquartered in Boulder, Colorado, has selected ... featuring complete Patient Access, Patient Accounting, and Claims ... also selected the MindLinc behavioral health EMR solution ...
... SAN DIEGO, Jan. 5, 2012  Essentialis, Inc., today announced ... with the life sciences-focused venture capital firm Vivo Ventures, ... for his expertise in business development and economic strategies, ... of Directors for Essentialis, a company focused on the ...
Cached Medicine Technology:Mental Health Partners Selects Stockell Healthcare's InsightCS® Revenue Cycle Information Management System 2Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors 2Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors 3
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... BOSTON (July 9, 2014) A retrospective study conducted ... and colleagues reports that among adults with intellectual and ... the number of years receiving dental care increased. The ... Care in Dentistry , may help improve interventions designed ... population. , The researchers reviewed the dental records ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... In ... of Technical Personnel in Ophthalmology (ATPO) proudly launched a new tool for ophthalmic professionals: ... , ... Paul, MN (Vocus) November 10, 2009 -- Compact, informative, and convenient are just a ...
... Darden Food Supplier Eliminates Workers Health and Retirement Benefits ... members from Teamster Local Union 890 presented Darden Restaurant Group, ... a letter today directed to Darden CEO Clarence Otis. In ... workers from Hollister, CA are seeking justice after a key ...
... Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: IFLG ... for the healthcare and commercial industries, today announced that ... to NASDAQ,s stockholder approval requirements, in accordance with NASDAQ ... this exception to complete a proposed plan of restructuring, ...
... Nov. 10 Roxane Laboratories, Inc. announced today the ... Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the ... available in bottles of 100 for immediate shipment to ... Tablets are AB rated to ACEON® (perindopril erbumine) tablets. ...
... , ... Rounds -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" ... Gulf Breeze, Fla. (Vocus) November ... Andrews Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at ...
... of vascular risk can be simplified, researchers say ... gauge blood cholesterol to determine vascular disease risk can ... measures levels of either total or high-density lipoprotein (HDL, ... that help transport cholesterol), without the need to have ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:Teamsters Look to Darden Restaurant Group for Justice 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:Cholesterol Measurements May Be Made Easier 2
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
... workstations is designed for laboratories with limited ... automation platform for routine sample preparation and ... throughput, process consistency and safety. Windows ... you to control the robotic and liquid ...
... miniGene LD is a reagent dispensing system ... and 1536-well microplates. This dispenser can be ... or wide orifice nozzle heads. Precise plate ... accurate dispensing to a variety of plate ...
Medicine Products: